HAE Financials

Income Statement
MetricQ2 2027Q1 2027Q4 2026Q3 2026Q2 2026
Revenue
357.8M
+5.4%
339.4M
-2.0%
346.4M
+2.2%
339.0M
+3.6%
327.3M
Cost of Revenue
147.2M
+7.8%
136.6M
-7.8%
148.1M
+8.5%
136.6M
-5.0%
143.8M
Gross Profit
210.5M
+3.8%
202.8M
+2.3%
198.2M
-2.1%
202.4M
+10.3%
183.6M
Operating Expenses
135.4M
-6.8%
145.3M
-34.3%
221.2M
+63.9%
135.0M
+7.9%
125.1M
R&D
17.0M
+5.1%
16.2M
+12.1%
14.4M
+1.8%
14.2M
-4.6%
14.9M
SG&A
118.4M
-0.5%
118.9M
-1.6%
120.9M
+10.8%
109.2M
+7.4%
101.6M
Operating Income
75.1M
+30.7%
57.5M
+349.5%
-23025000
-134.2%
67.4M
+15.2%
58.5M
EBITDA
102.9M
+21.7%
84.6M
+11.7%
75.7M
-21.8%
96.8M
+1.6%
95.3M
Net Income
46.3M
+40.3%
33.0M
+263.8%
-20147000
-145.0%
44.7M
+15.7%
38.7M
EPS (Basic)
$1.02
+39.7%
$0.73
+265.9%
$-0.44
-145.8%
$0.96
+18.5%
$0.81
EPS (Diluted)
$1.00
+38.9%
$0.72
+267.4%
$-0.43
-145.3%
$0.95
+17.3%
$0.81
Shares (Diluted)
46.5M
+1.7%
45.7M
-1.5%
46.4M
-1.2%
47.0M
-1.4%
47.7M
Haemonetics (HAE) — Financials